- Home
- VWAV vs SGMO Comparison
VWAV vs SGMO Comparison
Compare VWAV & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VWAV
- SGMO
- Stock Information
- Founded
- VWAV 2024
- SGMO 1995
- Country
- VWAV United States
- SGMO United States
- Employees
- VWAV N/A
- SGMO N/A
- Industry
- VWAV Computer Software: Prepackaged Software
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VWAV Technology
- SGMO Health Care
- Exchange
- VWAV Nasdaq
- SGMO Nasdaq
- Market Cap
- VWAV 162.2M
- SGMO 149.6M
- IPO Year
- VWAV N/A
- SGMO 2000
- Fundamental
- Price
- VWAV $10.75
- SGMO $0.40
- Analyst Decision
- VWAV
- SGMO Buy
- Analyst Count
- VWAV 0
- SGMO 7
- Target Price
- VWAV N/A
- SGMO $4.71
- AVG Volume (30 Days)
- VWAV 319.8K
- SGMO 4.8M
- Earning Date
- VWAV 11-19-2025
- SGMO 11-06-2025
- Dividend Yield
- VWAV N/A
- SGMO N/A
- EPS Growth
- VWAV N/A
- SGMO N/A
- EPS
- VWAV N/A
- SGMO N/A
- Revenue
- VWAV N/A
- SGMO $32,875,000.00
- Revenue This Year
- VWAV N/A
- SGMO $28.47
- Revenue Next Year
- VWAV N/A
- SGMO N/A
- P/E Ratio
- VWAV N/A
- SGMO N/A
- Revenue Growth
- VWAV N/A
- SGMO N/A
- 52 Week Low
- VWAV $2.06
- SGMO $0.39
- 52 Week High
- VWAV $18.41
- SGMO $2.84
- Technical
- Relative Strength Index (RSI)
- VWAV N/A
- SGMO 27.07
- Support Level
- VWAV N/A
- SGMO $0.41
- Resistance Level
- VWAV N/A
- SGMO $0.53
- Average True Range (ATR)
- VWAV 0.00
- SGMO 0.04
- MACD
- VWAV 0.00
- SGMO -0.01
- Stochastic Oscillator
- VWAV 0.00
- SGMO 2.16
About VWAV VisionWave Holdings Inc. Common Stock
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.